Ask about this productRelated genes to: SLC45A3 antibody
- Gene:
- SLC45A3 NIH gene
- Name:
- solute carrier family 45 member 3
- Previous symbol:
- PCANAP6, PCANAP2, PCANAP8
- Synonyms:
- IPCA-6, prostein, IPCA-2, IPCA-8
- Chromosome:
- 1q32.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-04-13
- Date modifiied:
- 2015-12-08
Related products to: SLC45A3 antibody
Related articles to: SLC45A3 antibody
- The p.R4810K founder mutation in the gene confers susceptibility to moyamoya disease (MMD) and non-MMD intracranial artery disease. However, penetrance is incomplete, and the underlying molecular mechanism remains unknown. - Source: PubMed
Publication date: 2025/12/23
Mineharu YoheiKamata TakahikoTomoto MeiSato NoriakiTamada YoshinoriFunaki TakeshiOichi YukiHarada Kouji HKoizumi AkioKimura TetsuakiInoue IturoOkuno YasushiMiyamoto SusumuArakawa Yoshiki - DNA methylation influences gene expression and is involved in numerous biological processes, including fat production. It is involved in lipid generation in numerous animal species, including poultry. However, the effect of DNA methylation on adipogenesis in chickens remains unclear. - Source: PubMed
Publication date: 2025/03/20
Chao XiaohuanGuo LijinHu MeilingYe MaoFan ZhexiaLuan KangChen JiahaoZhang ChunleiLiu ManqingZhou BoZhang XiquanLi ZhenhuiLuo Qingbin - Although B-cell acute lymphoblastic leukemia (B-cell ALL) survival rates have improved in recent years, Hispanic children continue to have poorer survival rates. There are few tools available to identify at the time of diagnosis whether the patient will respond to induction therapy. Our goal was to identify predictive biomarkers of treatment response, which could also serve as prognostic biomarkers of death, by identifying methylated and differentially expressed genes between patients with positive minimal residual disease (MRD+) and negative minimal residual disease (MRD-). DNA and RNA were extracted from tumor blasts separated by immunomagnetic columns. Illumina MethlationEPIC and mRNA sequencing assays were performed on 13 bone marrows from Hispanic children with B-cell ALL. Partek Flow was used for transcript mapping and quantification, followed by differential expression analysis using DEseq2. DNA methylation analyses were performed with Partek Genomic Suite and Genome Studio. Gene expression and differential methylation were compared between patients with MRD-/- and MRD at the end of induction chemotherapy. Overexpressed and hypomethylated genes were selected and validated by RT-qPCR in samples of an independent validation cohort. The predictive ability of the genes was assessed by logistic regression. Survival and Cox regression analyses were performed to determine the association of genes with death. , , , , , , , , and were overexpressed and hypomethylated in MRD patients. Overexpression was also validated by RT-qPCR. , , , and can predict refractoriness, but is the best predictor. Additionally, higher expression of increases the probability of non-response, death, and the risk of death. Finally, overexpression, together with MRD+, are associated with poorer survival, and together with overexpression of and , it could improve the risk classification of patients with normal karyotype. is a potential predictive biomarker of treatment response and death in children with B-cell ALL. - Source: PubMed
Publication date: 2024/04/30
Torres-Llanos YuliethZabaleta JovannyCruz-Rodriguez NatalyQuijano SandraGuzmán Paula Carolinade Los Reyes IlianaPoveda-Garavito NathalyInfante AnaLopez-Kleine LilianaCombita Alba Lucía - Prostein (P501S), also termed solute carrier family 45 member 3 (SLC45A3) is an androgen regulated protein which is preferentially expressed in prostate epithelial cells. Because of its frequent expression in prostate cancer, prostein was suggested a diagnostic prostate cancer marker. - Source: PubMed
Publication date: 2024/01/13
Viehweger FlorianBöcker CarolaWeidemann SörenFreytag MortonMenz AnneBüscheck FranziskaLuebke Andreas MPutri DevitaKluth MartinaHube-Magg ClaudiaHinsch AndreaLennartz MaximilianLutz FlorianReiswich ViktorHöflmayer DorisFraune ChristophMöller KatharinaBernreuther ChristianLebok PatrickSauter GuidoSteurer StefanDum DavidMarx Andreas HSimon RonaldKrech TillClauditz Till SJacobsen FrankGorbokon NataliaBurandt EikeMinner SarahKind Simon - The impact of tumor focality on prostate cancer (PCa) prognosis has been addressed in several studies with conflicting results. Tumor foci from multifocal (MF) PCa can show highly heterogeneous molecular features. Our aim was to analyze the protein expression of PTEN, SPOP, SLC45A3, ETV1, ERG and the "triple hit" (ERG overexpression, PTEN plus SLC45A3 loss) in unifocal (UF) and MF PCa, to evaluate their value as prognostic markers according to focality, and the role of tumor heterogeneity in MF disease. PTEN, SPOP, SLC45A3, ETV1 and ERG immunohistochemical expression was evaluated in 185 PCa from 9 TMAs, 51 UF and 134 MF. In a subset of 69 MF cases, the dominant and secondary foci (DF and SF) were compared. Heterogeneity was considered when both tumor foci presented different expression patterns. Relationship with clinicopathological features was also analyzed. MF PCa was diagnosed in significantly younger patients when compared to UF ones (p = 0.007). ETV1 overexpression was associated with UF disease (p = 0.028). A shorter time to PSA recurrence was related to SLC45A3 wt expression in UF PCa (p = 0.052), and to SPOP expression loss (p = 0.043) or "triple hit" phenotype in MF PCa (p = 0.041). In MF cases, PTEN loss, SLC45A3 loss and "triple hit" phenotype were associated with the DF and had significant heterogeneity. In conclusion, our results indicate that UF and MF PCa have relevant and consistent molecular differences. The analysis of an immunohistochemical panel, composed by PTEN, SPOP, SLC45A3, ETV1 and ERG, could be useful to predict outcome in MF cases. - Source: PubMed
Publication date: 2023/11/28
Segalés LauraJuanpere NuriaGallarín NereaLorenzo MartaLópez DavidPerera-Bel JúliaRodriguez-Vida AlejoFumadó LluísCecchini LluísBellmunt JoaquimLloreta-Trull JosepHernández-Llodrà Silvia